About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Massachusetts | 601 Studies

Clinical Trials LymphomaMassachusetts

Lymphoma Clinical Trials in Massachusetts

Find 601 clinical trials for lymphoma near Massachusetts. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 181-200 of 601 trials

RecruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaThe purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung…NCT03460977·Tucson, Arizona and 84 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedLenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaThis phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned…NCT02568553·Birmingham, Alabama and 23 others

RecruitingTesting the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaThis phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in…NCT04803201·Little Rock, Arkansas and 95 others

CompletedA Study Of PF-05082566 As A Single Agent And In Combination With RituximabA study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20…NCT01307267·Duarte, California and 41 others

RecruitingEpco, Zanu, Ritux for R/R FL or MZLThe purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory…NCT06563596·Boston, Massachusetts and 2 others

RecruitingBRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaThis study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by…NCT06854003·Phoenix, Arizona and 6 others

RecruitingA Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasThis is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients…NCT05475925·Birmingham, Alabama and 36 others

RecruitingA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasThe purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of…NCT04104776·Tampa, Florida and 79 others

RecruitingMB-105 in Patients With CD5 Positive T-cell LymphomaThis is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).NCT06534060·San Diego, California and 11 others

RecruitingA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaThe purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination…NCT04669171·Boston, Massachusetts and 11 others

CompletedEfficacy and Safety Study of Fostamatinib Tablets to Treat B-cell LymphomaPatients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16…NCT00446095·Los Angeles, California and 10 others

TerminatedGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaThis phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with…NCT01088763·Palo Alto, California and 11 others

CompletedA Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesTo assess safety and tolerability, describe the dose-limiting toxicities, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered…NCT03106428·Los Angeles, California and 13 others

CompletedRituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard…NCT00329030·New Haven, Connecticut and 35 others

CompletedCombination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy, such as doxorubicin, vinblastine, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die.NCT00086801·San Francisco, California and 46 others

UnknownCombination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaThe purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination…NCT02481310·Chicago, Illinois and 4 others

CompletedMinimal Residual Disease in Peripheral T-cell LymphomaAs T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this…NCT03297697·Boston, Massachusetts and 2 others

CompletedEscalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaThe purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic…NCT01351935·Huntsville, Alabama and 12 others

CompletedBrentuximab Vedotin Plus AVD in Limited-stage Hodgkin LymphomaBrentuximab is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a chemotherapy molecule.NCT01534078·Tampa, Florida and 3 others

Active not recruitingStudy to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaThe purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455)…NCT04756726·Phoenix, Arizona and 12 others

PreviousPage 10 of 31Next

Other Conditions in Massachusetts

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia